dihydroalprenolol has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cynis, H; Demuth, HU; Hartlage-Rübsamen, M; Jäger, C; Koch, B; Morawski, M; Rossner, S; Schilling, S; Schliebs, R; Waniek, A; Zeitschel, U | 1 |
| Fujiwara, M; Kameyama, M; Shimohama, S; Taniguchi, T | 1 |
2 other study(ies) available for dihydroalprenolol and Alzheimer Disease
| Article | Year |
|---|---|
Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Aminoacyltransferases; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Autoradiography; Cells, Cultured; Dihydroalprenolol; Female; Green Fluorescent Proteins; Hippocampus; Humans; Male; Mice; Mice, Transgenic; Neurons; Potassium Chloride; Prazosin; Protein Binding; Pyrrolidonecarboxylic Acid; Receptors, Adrenergic; Time Factors; Tritium; Yohimbine | 2011 |
Changes in beta-adrenergic receptor subtypes in Alzheimer-type dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebellum; Dihydroalprenolol; Female; Hippocampus; Humans; Male; Metoprolol; Putamen; Receptors, Adrenergic, beta; Temporal Lobe; Thalamus; Tissue Distribution | 1987 |